

Appl. No. : 10/719,547
Filed : November 21, 2003

AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** A temperature-sensitive, host-range restricted mutant flavivirus, designated mutant 200, 201, wherein said virus comprises flavivirus having a phenotype in which the viral genome is modified by the introduction of a mutation, singly or in combination, taken from the group consisting of the mutations of Table 37, wherein said mutation is charge-cluster-to-alanine mutations at amino acids 2687 and 2688 of the NS5 gene, where amino acid position is given for the polyprotein of dengue virus type 4 200, 201.
2. **(Original)** The flavivirus of claim 1, further comprising the Δ30 mutation.
3. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 1.
4. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 2.
5. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 3.
6. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a dengue virus type 4.
7. **(Original)** The flavivirus of claim 1, wherein the flavivirus is a chimeric virus.
8. **(Original)** The chimeric virus of claim 7 having a dengue 1 backbone.
9. **(Original)** The chimeric virus of claim 7 having a dengue 2 backbone.
10. **(Original)** The chimeric virus of claim 7 having a dengue 3 backbone.
11. **(Original)** The chimeric virus of claim 7 having a dengue 4 backbone.
12. **(Original)** The flavivirus of claim 1, wherein the phenotype is temperature sensitivity in Vero cells or the human liver cell line HuH-7.
13. **(Canceled)**
14. **(Canceled)**
15. **(Canceled)**
16. **(Currently amended)** A pharmaceutical composition comprising a pharmacologically acceptable vehicle and a flavivirus according to any of claims 1-12 1-15.
- 17.-32. **(Canceled)**